Search
for
Sort by
Research 91–120 of 1000+
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Topical and intralesional therapies for alopecia areata
- Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
- Immune Microenvironment of Hair Follicles in Tumor Immunotherapy
- Dermatologic Adverse Events from Cancer Treatments
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!
- The evolution of primary multimodality treatment in resectable breast cancer
- Cancer Treatments and Alopecia: A Systematic Review
- EXPERIENCES OF CANCER PATIENTS RECEIVING CHEMOTHERAPY IN ONCOLOGY FACILITIES: A SCOPING REVIEW PROTOCOL v1
- Fibroblast heterogeneity and functions: insights from single-cell sequencing in wound healing, breast cancer, ovarian cancer and melanoma
- Post-oncologic skin health: cutaneous recovery and rehabilitation after cancer treatments
- Impact of Chemotherapeutic Drug on People living with Cancer
- Hair disorders in patients with cancer
- Redefining hormone resistance in prostate cancer
- Recent discoveries and developments of androgen receptor based therapy for prostate cancer
- Adverse Hair Reactions to New Targeted Therapies for Cancer
- Sexual dimorphism of COVID-19 inspires drug repositioning and host-targeting immunotherapy for viral pneumonia
- Psychological burden of alopecia areata in patients with cancer: A narrative review
- Nobiletin-loaded composite penetration enhancer vesicles restore the normal miRNA expression and the chief defence antioxidant levels in skin cancer
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- British Hair and Nail Society
- Acquired scalp alopecia. Part II: A review
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
- Physiological Doses of Red Light Induce IL‐4 Release in Cocultures between Human Keratinocytes and Immune Cells
- Survey on adverse events associated with drug therapy for breast cancer patients
- The IL-33/ST2 axis and tissue Treg maintain epithelial homeostasis and restrain cancer development in the skin